CORONA Remedies Commercialises EU-GMP Approved Women’s Hormone Manufacturing Facility at Ahmedabad

highlight:

What Happened ?

Key Details

Facility Highlights:

• Location:
  • Bhayla, Ahmedabad.
• Regulatory Standard:
  • EU-GMP approved manufacturing facility.
• Manufacturing Area:
  • Approximately 1.0 lakh sq. ft.
• Annual Production Capacity:
  • 194 million tablets/capsules
  • 1.5 million ointments/gels
• Capacity Expansion:
  • Expected to increase in-house hormone manufacturing capacity by nearly 20%.
• Therapeutic Focus:
  • Women’s healthcare and hormone therapies.
• Dosage Forms Supported:
  • Tablets
  • Soft gel capsules
  • Ointments
  • Gels

Advanced Manufacturing Technologies:

• Fully integrated closed-loop manufacturing systems.
• 21 CFR-compliant equipment.
• Quality by Design (QbD)-based manufacturing.
• Precision-controlled gelatin processing systems.
• Real-time online process monitoring.
• Digital process controls for improved product consistency and operational efficiency.

Strategic Importance:

• Expands CORONA’s dedicated hormone manufacturing capabilities.
• Supports both domestic and international pharmaceutical markets.
• Strengthens manufacturing infrastructure for complex hormone formulations.
• Reinforces the company’s long-term strategy in women’s healthcare.

Note:

• The facility was inaugurated by Chairman Dr. K. L. Mehta alongside long-serving women employees, highlighting the company’s commitment to women’s healthcare and pharmaceutical innovation.

Risk Analysis

Summary:

• The facility is operational and commercial production has commenced. Future financial benefits will depend on capacity utilization, regulatory compliance, product demand and execution across domestic and export markets.

Key Risks:

• Revenue contribution has not been disclosed.
• Commercial ramp-up may take time before reaching optimal utilization.
• Pharmaceutical manufacturing remains subject to stringent regulatory inspections.
• Growth depends on sustained demand in women’s healthcare therapies.

Worst Case:

• Lower-than-expected utilization or regulatory challenges could delay the realization of operational and financial benefits from the new facility.

Risk Level: Medium

Company Commentary

• Commercial production has commenced at the EU-GMP approved hormone manufacturing facility.
• The facility is designed to manufacture complex hormone-based pharmaceutical products.
• Annual production capacity includes 194 million tablets/capsules and 1.5 million ointments/gels.
• The project is expected to increase in-house hormone manufacturing capacity by nearly 20%.
• Management believes the investment strengthens India’s pharmaceutical manufacturing ecosystem and supports global-quality women’s healthcare products.